Window Trial of Fluorescently Labeled Panitumumab (Panitumumab-IRDye800) in Head and Neck Cancer

NCT06819228 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

RECRUITING

Status

18

Enrollment

OTHER

Sponsor class

Conditions

HNSCC
HNSCC,Larynx, Pharynx and Oral Cavity
SCC - Squamous Cell Carcinoma

Interventions

DRUG: Panitumumab IRDye 800

Sponsor

Vanderbilt-Ingram Cancer Center